<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): July 27, 2000
ZONAGEN, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Delaware 0-21198 76-0233274
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer Identification No.)
incorporation or organization)
</TABLE>
2408 Timberloch Place, Suite B-4
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant's telephone number, including
area code)
<PAGE> 2
Item 5. Other Events
On July 27, 2000, Zonagen, Inc. issued a press release announcing
its decision to seek strategic alternatives and to reduce expenditures as a
result of the regulatory delay of VASOMAX(TM). The action will result in the
dismissal of more than one-half of the Company's work force.
The press release is filed as an exhibit to this Current Report on
Form 8-K and is incorporated by reference herein.
Item 7. Exhibits
Exhibit 99.1 -- Press Release dated July 27, 2000.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ZONAGEN, INC.
Date: August 8, 2000
By: /s/ Louis Ploth, Jr.
-------------------------------
Louis Ploth, Jr.
Vice President, Finance
3
<PAGE> 4
EXHIBIT INDEX
----------------
Exhibit No.
-----------
99.1 Press Release dated July 27, 2000.
